There were 16 adults assigned to each group, with 15 participants in each group completing the study. Adverse events were monitored in both groups. The Diabetes Treatment Satisfaction Questionnaire was administered at baseline and 26 weeks. Blood glucose testing was self-performed by participants twice weekly. Follow-up visits occurred at 8, 16 and 26 weeks. The dulaglutide group received 0.75 mg doses for all 26 weeks. The semaglutide group received 0.25 mg doses for 4 weeks, followed by 0.5 mg for the remainder of the trial. Participants were randomly assigned to switch to semaglutide or dulaglutide therapy. Researchers recruited 32 adults aged 21 years and older with type 2 diabetes receiving 0.6 mg or 0.9 mg liraglutide who were treated at Yokosuka Kyosai Hospital in Japan from September 2020 to March 2022. This result may be explained by the fact that the effects of GLP-1 receptor agonists on the brain differ between semaglutide and dulaglutide.” “In contrast, semaglutide 0.5 mg can be expected to reduce body weight by approximately 2 kg over 26 weeks. “Based on these findings, it was clinically confirmed that in Japanese patients, dulaglutide 0.75 mg does not cause any change in body weight,” Yasuo Terauchi, PhD, professor in the department of endocrinology and metabolism at Yokohama City University Graduate School of Medicine in Japan, and colleagues wrote. At the end of the study, the semaglutide group had decreases in body weight and HbA1c compared with baseline, whereas there were no changes in either metric for the dulaglutide group.ĭata were derived from Iijima T, et al. In findings from a randomized controlled trial published in the Journal of Diabetes Investigation, 32 adults with type 2 diabetes receiving liraglutide (Saxenda, Novo Nordisk) at baseline were randomly assigned to switch to semaglutide (Ozempic/Wegovy, Novo Nordisk) or dulaglutide (Trulicity, Eli Lilly) for 26 weeks. Adults switching to dulaglutide had no change in body weight or HbA1c.Īdults with type 2 diabetes who switched from liraglutide to semaglutide therapy had greater reductions in HbA1c and body weight at 26 weeks than those who switched to dulaglutide, according to study data from researchers in Japan.
Adults with type 2 diabetes using liraglutide had a 0.42% reduction in HbA1c at 26 weeks after switching to semaglutide.If you continue to have this issue please contact to Healio Key takeaways:
0 kommentar(er)
